AZNAstraZenecaRunning, no new patients
Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer
Non-muscle-invasive Bladder Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Apr 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 1,018 (final count)
- Started
- May 14, 2018
- Main results expected
- Apr 3, 2025
- Fully finished
- Oct 3, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The efficacy of Durvalumab + BCG (induction plus maintenance) combination therapy compared to SoC in terms of Disease free survival (DFS) in patients with NMIBC
Measured over: Up to 4 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-04-03, no fading
Raw record changes
- none yet
Trial ID NCT03528694 · record last updated 2026-07-07 · checked 2026-11-09 15:47 UTC